Human Milk-Derived L. reuteri FN041 in Colitis: Microbial and Metabolic Remodeling in DSS Mouse Models

Study Background and Research Question

Ulcerative colitis (UC), a chronic form of inflammatory bowel disease (IBD), continues to pose substantial clinical challenges due to its persistent inflammation of the colon and rectum, rising global incidence, and considerable rates of therapeutic resistance. Evidence implicates a complex interplay between host genetics, immune dysregulation, impaired intestinal barrier integrity, and—crucially—gut microbiota imbalance in both disease onset and progression. While probiotic interventions have shown promise in enhancing mucosal barrier function and reducing inflammation, the efficacy and mechanisms of specific strains, particularly those derived from human milk, in UC remain underexplored.

The reference study (Luo et al., 2025) addresses this gap by investigating whether the probiotic Limosilactobacillus reuteri FN041, isolated from human breast milk, can prevent or ameliorate DSS-induced colitis in mice, and elucidates the underlying microbiota and metabolic mechanisms.

Key Innovation from the Reference Study

The central innovation of this research lies in demonstrating that a human milk-derived L. reuteri strain (FN041) exerts significant protective effects against experimental colitis. Unlike prior UC probiotic studies that mainly characterized symptom reduction or generic immunomodulation, this work integrates metagenomic and metabolomic analyses to substantiate that FN041's benefits are tightly linked to remodeling of gut bacterial communities and restoration of host–microbial metabolic interactions. Notably, the study identifies both compositional and functional microbial shifts, as well as specific metabolite markers disrupted in colitis and partially normalized by FN041 administration.

Methods and Experimental Design Insights

The study employed a well-established dextran sodium sulfate (DSS)-induced mouse model of colitis to mimic human UC pathology. Mice were orally administered L. reuteri FN041 throughout the induction and progression of colitis. Disease severity was quantified using weight loss, colon length, and validated scoring for disease activity and histological damage.

To dissect mechanisms, the authors measured local and systemic inflammatory markers (including IL-6 and IL-10), oxidative stress indicators (malondialdehyde), and tight junction protein expression as proxies for mucosal barrier integrity. Serum lipopolysaccharide and D-lactate levels were assessed to gauge permeability. Crucially, fecal metagenomics and cecal metabolomics were performed to profile the microbiota and metabolic landscape, respectively. Correlation analyses linked clinical outcomes, microbial taxa, and metabolite fluctuations.

Protocol Parameters

• DSS-induced colitis: Mice received DSS in drinking water to induce acute colitis; FN041 was administered orally during both induction and progression phases.
• Inflammatory marker assessment: Colonic tissues and serum were collected for ELISA-based quantification of cytokines (IL-6, IL-10) and oxidative stress markers.
• Microbiota/metabolite profiling: Fecal samples were subjected to shotgun metagenomic sequencing; cecal contents underwent LC-MS-based metabolomic analysis.
• Tight junction analysis: Immunohistochemistry and Western blotting used to detect expression of key tight junction proteins (e.g., ZO-1, occludin).

Core Findings and Why They Matter

Luo et al. report that FN041 administration significantly mitigated DSS-induced weight loss, colon shortening, and histopathological damage. Disease Activity Index and Histological Index scores improved, reflecting both symptomatic and underlying tissue protection.

Importantly, FN041 reduced pro-inflammatory cytokine (IL-6) levels while increasing anti-inflammatory IL-10, and suppressed oxidative stress. Tight junction protein expression was restored, and markers of mucosal permeability (serum LPS, D-lactate) were reduced, indicating improved barrier function.

Metagenomic profiling revealed that FN041 counteracted DSS-induced microbiota dysbiosis by increasing the abundance of beneficial taxa (e.g., Lactobacillus, Akkermansia) and suppressing pro-inflammatory or tissue-damaging bacteria. Metabolomic analysis identified five key metabolites (such as 1-myristoyl-sn-glycero-3-phosphocholine and gamma-L-glutamylputrescine) that were perturbed by colitis and partially normalized by probiotic treatment. Correlation analyses confirmed interdependence among clinical, microbial, and metabolic parameters, suggesting a causative role for microbiota and metabolite restoration in the observed therapeutic effects.

Comparison with Existing Internal Articles

While the reference study does not directly address protein quantification, robust analysis of host and microbial proteins is critical in microbiome and mucosal immunology research. Internal articles, such as "BCA Protein Assay Kit: Precision Bicinchoninic Acid Protein Quantification", highlight how the BCA Protein Assay Kit enables reliable measurement of protein concentrations in complex matrices, including cell lysates and tissue extracts—a workflow compatible with studies investigating gut barrier proteins or inflammatory mediators.

Likewise, "Applied Workflows with BCA Protein Assay Kit for Protein Quantification" details optimized protocols for quantifying protein content in diverse biological samples, supporting mechanistic studies of barrier function—an essential parameter in both colitis and blood–brain barrier pathophysiology. These resources provide complementary technical guidance for researchers translating findings from animal models to clinical or in vitro systems requiring accurate protein quantification.

Limitations and Transferability

Despite compelling evidence for L. reuteri FN041's efficacy in the DSS mouse model, several limitations warrant consideration. First, translation to human UC is not guaranteed, given interspecies differences in immune and microbial dynamics. The probiotic's effects were shown to be partially but not fully restorative, as some metabolites and microbial populations did not return to healthy baseline levels. The study's reliance on a single model and strain restricts generalizability across UC subtypes and patient heterogeneity. Furthermore, while metagenomic and metabolomic correlations are suggestive, direct causation between specific taxa/metabolites and clinical improvement remains to be mechanistically validated.

Research Support Resources

For researchers aiming to extend these findings or conduct related mechanistic studies, reliable protein quantification is essential—particularly when evaluating mucosal barrier proteins, inflammatory mediators, or verifying sample normalization in microbiome and metabolomics workflows. The BCA Protein Assay Kit (SKU: K4101) provides a sensitive, reproducible bicinchoninic acid protein quantification platform compatible with diverse sample types, including gut tissue lysates. This assay supports downstream applications such as Western blotting and ELISA, facilitating robust biochemical and molecular biology research in gut microbiome studies. For further workflow optimization and troubleshooting, refer to the internal article on precision protein quantification using the BCA Protein Assay Kit.